HealthTech M&A Multiples November 2025: Current Trends and Variables driving valuations

As of November 2025, the HealthTech M&A market has stabilized following the recalibration of 2023–2024. While we are not seeing the "growth at all costs" valuations of 2021, multiples have recovered for high-quality assets. The primary theme for late 2025 is selectivity. Buyers (both strategic and Private Equity) are deploying capital aggressively but only for companies with proven unit economics, clear paths to profitability, or "must-have" AI infrastructure.

1. Current Valuation Multiples (November 2025)

The spread between "average" and "premium" assets has widened significantly. Companies with proprietary AI or strong recurring revenue (SaaS) command the highest premiums.

Revenue Multiples (EV / LTM Revenue)

Premium AI & Data > 6.0x – 8.0x+ > Companies with proven proprietary algorithms (not just wrappers) or clean, actionable data sets (e.g., drug discovery, imaging AI).

Value-Based Care Tech > 5.5x – 7.0x > Platforms enabling risk-bearing models (e.g., population health, remote monitoring).

Telehealth (Hybrid) > 5.0x – 7.0x > Mature platforms with hybrid (virtual + in-person) capabilities. Pure-play telehealth sees lower multiples.

General HealthTech > 4.0x – 6.0x > The "standard" range for growing digital health SaaS with average retention/margins.

Unprofitable/Early Stage > 3.0x – 4.0x > Startups with high burn rates or unclear ROI are seeing significant valuation compression

Current market intelligence suggests the following HealthTech M&A landscape for November 2025.

EBITDA Multiples (EV / LTM EBITDA)

Used for mature, profitable companies and tech-enabled services.

Profitable HealthTech > 10x – 14x > Established software firms with >20% EBITDA margins.

Tech-Enabled Services > 10x – 12x > Service-heavy models (RCM, provider services) that scale slower than pure software.

Broader Healthcare > ~12.8x > Median across the wider healthcare sector (hospitals, services, devices).

2. The 4 Variables Driving Valuations Now

If you are looking to understand why one company trades at 4x and another at 8x, it comes down to these four variables:

A. The "AI Premium" (Reality vs. Hype) 

In 2025, buyers have moved past the hype phase. You don't get a premium just for saying "GenAI."

Driver: Buyers are paying up for workflow integration. Does the AI actually reduce administrative burden or improve diagnostic accuracy today?

Impact: Validated AI solutions in diagnostics, drug discovery, and RCM (Revenue Cycle Management) are seeing the highest multiples (often 8x+ revenue).

B. Path to Profitability (Rule of 40)

The "growth at all costs" era is definitively over.

Driver: Private Equity (PE) firms—who are sitting on record "dry powder"—are prioritizing the "Rule of 40" (Growth % + Profit Margin % > 40).

Impact: Companies burning cash without a clear 12-18 month path to break-even are seeing offers with heavy structures (earn-outs) or significantly compressed multiples (3x revenue).

C. The Value-Based Care (VBC) "Enablers"

Healthcare is still shifting from Fee-For-Service to Value-Based Care.

Driver: Payers and large Health Systems are desperate for tech that helps them manage risk and patient populations outside the hospital walls.

Impact: Tech that proves it can lower cost of care (e.g., Remote Patient Monitoring, Chronic Disease Management) commands a premium because it directly impacts the buyer's bottom line.

D. Regulatory & Political Clarity

Driver: With the 2024 US election cycle in the rearview, regulatory pathways for digital health (particularly AI and reimbursement codes) have stabilised.

Impact: This reduced uncertainty has encouraged large strategic buyers (Pharma, MedTech) to resume "mega-mergers" and consolidation plays.

3. Notable HealthTech Deal Activity (2025 Examples)

The market has seen a resurgence of "Platform" deals—large strategic acquisitions designed to build dominant positions in specific verticals.

Johnson & Johnson acquires Intra-Cellular Therapies ($14.6B): Bio-Pharma Tech. Highlights the massive premium paid for late-stage, de-risked assets in the central nervous system space.

Clearlake Capital acquires ModMedicine ($5.3B): Practice Management SaaS. A classic PE play for a mature, profitable "system of record" widely used by specialty practices.

Stryker acquires Inari Medical ($4.9B): MedTech. Demonstrates the continued appetite for medical devices that offer minimally invasive solutions with clear reimbursement pathways.

Optum acquires Amedisys ($3.9B): Home Health / Tech-Enabled Services. (Note: Heavily scrutinised by regulators). Signals the continued push by payers to own the "home" setting of care.

Roper Technologies acquires CentralReach ($1.9B): Behavioral Health SaaS. Highlights the strong demand for vertical-specific software, specifically in the autism/behavioral health space.

4. Sub-Sector Snapshot

Provider Tech (RCM & IT): Stable. Hospitals are squeezed financially, so they are buying tech that automates back-office tasks (RCM) to save money. High volume of deals, moderate multiples.

Life Sciences IT (Drug Discovery): Bullish. Pharma giants facing patent cliffs are aggressively buying AI-driven drug discovery platforms to speed up R&D.

Digital Health (Consumer/Telehealth): Bearish / Mixed. The "Direct-to-Consumer" model is struggling with high customer acquisition costs. Valuation multiples here remain depressed unless the company has pivoted to B2B (selling to employers/payers).

To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email [email protected]